Trials / Withdrawn
WithdrawnNCT02226458
An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Edison Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 3 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that EPI-743 may provide clinical benefit to children with Autism Spectrum Disorder.
Detailed description
An Exploratory Open Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children with Autism Spectrum Disorder
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPI-743 |
Timeline
- Start date
- 2014-10-31
- Primary completion
- 2015-11-30
- Completion
- 2016-01-31
- First posted
- 2014-08-27
- Last updated
- 2022-01-21
Source: ClinicalTrials.gov record NCT02226458. Inclusion in this directory is not an endorsement.